BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: A global developer, manufacturer, and marketer of medical devices used in interventional medical specialties, including Cardiac Rhythm Management, Coronary Stents, Peripheral Interventions, Neurovascular, Endosurgery, and Neuromodulation.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 2% ($36 million) year-over-year. Excluding foreign currency impacts and divested businesses, organic sales increased 4%.
• Profitability Collapse: Operating income plummeted from $580 million to $11 million, and the company reported a net loss of $13 million compared to a net income of $322 million in the prior year.
• Margin Compression: Gross margin decreased 190 basis points to 69.8%, primarily driven by a shift in sales mix toward the lower-margin PROMUS stent system (supplied by Abbott) and unfavorable foreign currency impacts.
• Significant Charges: The quarter included $287 million in pre-tax litigation-related charges and $37 million in restructuring charges. This contrasts with Q1 2008, which included a $250 million gain on divestitures.
• Debt Reduction: Total debt decreased by approximately $500 million due to prepayments, though cash reserves also declined significantly due to investing and financing activities.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Restructuring Initiatives: The company is executing a 2007 Restructuring plan and a new Plant Network Optimization plan (approved Jan 2009) to reduce costs and improve gross margins. Total estimated pre-tax charges for the new plan are $135–$150 million.
• Product Strategy: Management emphasizes a two-drug platform strategy (TAXUS and PROMUS). While PROMUS sales are growing, they have lower margins than TAXUS. The company plans to launch the internally manufactured PROMUS Element stent in late 2009 (EMEA) and mid-2012 (US/Japan) to improve margins.
• Market Position: The company maintains a leadership position in the drug-eluting stent market (estimated 44% global share) and Cardiac Rhythm Management (CRM), with U.S. CRM sales growing 11%.

Risks and Contingencies

• Litigation: Significant ongoing patent litigation with Johnson & Johnson regarding stent systems. A recent Court of Appeals ruling resulted in a $237 million charge. The company also settled litigation with Dr. Bruce Saffran for $50 million.
• Regulatory Compliance: The company remains subject to an FDA corporate warning letter regarding quality system issues, though it has made significant progress toward compliance.
• Supply Chain: Reliance on Abbott Laboratories for the supply of PROMUS stent systems creates supply chain risks and margin constraints.
• Financial Covenants: The company amended its credit facility in February 2009 to provide flexibility regarding litigation and restructuring charges. It remains in compliance with leverage and interest coverage covenants.

Investor Verification Checklist

• Litigation Exposure: Verify the status of the Johnson & Johnson patent infringement appeals and the potential for additional accruals beyond the $237 million charged.
• Margin Recovery: Monitor the sales mix between TAXUS and PROMUS stents and the timeline for the launch of the higher-margin PROMUS Element to assess gross margin stabilization.
• Cash Flow Sustainability: Review the impact of ongoing litigation settlements and restructuring cash outflows on liquidity, given the reduction in cash reserves from $1.64 billion to $897 million.
• Debt Covenant Compliance: Confirm continued compliance with the amended financial covenants, specifically the leverage ratio, as restructuring and litigation charges are excluded from EBITDA calculations under the new terms.
• Regulatory Status: Track the resolution of the FDA corporate warning letter and any potential impact on product approvals or market access.